Is it cost-effective to introduce rotavirus vaccination in the Dutch national immunization program?

被引：43

作者：

Mangen, Marie-Josee J. ^{[1
,2
]}

van Duynhoven, Yvonne T. H. P. ^{[2
]}

Vennema, Harry ^{[2
]}

van Pelt, Wilfrid ^{[2
]}

Havelaar, Arie H. ^{[2
,3
]}

de Melker, Hester E. ^{[2
]}

机构：

[1] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, NL-3508 GA Utrecht, Netherlands

[2] Natl Inst Publ Hlth & Environm, NL-3720 BA Bilthoven, Netherlands

[3] Univ Utrecht, Inst Risk Assessment Sci, Utrecht, Netherlands

来源：

VACCINE | 2010年 / 28卷 / 14期

关键词：

Rotavirus vaccination; National immunization program; Cost-effectiveness; RISK-FACTORS; DISEASE BURDEN; GASTROENTERITIS; ENGLAND; HOSPITALIZATIONS; NETHERLANDS; INFECTIONS; EFFICACY; INFANTS; CAMPYLOBACTER;

D O I：

10.1016/j.vaccine.2010.01.014

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

This study assessed whether the inclusion of two rotavirus (RV) vaccines in the Dutch national immunization programme is cost-effective. Costs and outcomes in unvaccinated and vaccinated populations are compared for a time period of 20 years. In the baseline, assuming competitive market forces in relation to vaccine costs, Rotarix (R) is more cost-effective than RotaTeq (R), resulting in a cost-utility ratio (CUR) of (sic) 53,000 per DALY (third payer perspective) and (sic) 49,000 per DALY (societal perspective), but both considered as being not cost-effective. Vaccine-related costs, annual epidemic-size, and indirect protection are the major factors that determine cost-effectiveness of RV vaccination. (C) 2010 Elsevier Ltd. All rights reserved.

引用

页码：2624 / 2635

页数：12

共 64 条

[31] Estimating the number of deaths with rotavirus as a cause in England and Wales [J].

Jit, Mark ;

Pebody, Richard ;

Chen, Mark ;

Andrews, Nick ;

Edmunds, W. John .

HUMAN VACCINES, 2007, 3 (01) :23-26

[32] The cost-effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe [J].

Jit, Mark ;

Bilcke, Joke ;

Mangen, Marie-Josee J. ;

Salo, Heini ;

Melliez, Hugues ;

Edmunds, W. John ;

Yazdan, Yazdanpanah ;

Beutels, Philippe .

VACCINE, 2009, 27 (44) :6121-6128

[33]

KEMMEREN JM, 2006, 330080001 NAT I PUBL

[34] TOWARDS A NEW APPROACH FOR ESTIMATING INDIRECT COSTS OF DISEASE [J].

KOOPMANSCHAP, MA ;

VANINEVELD, BM .

SOCIAL SCIENCE & MEDICINE, 1992, 34 (09) :1005-1010

[35] THE FRICTION COST METHOD FOR MEASURING INDIRECT COSTS OF DISEASE [J].

KOOPMANSCHAP, MA ;

RUTTEN, FFH ;

VANINEVELD, BM ;

VANROIJEN, L .

JOURNAL OF HEALTH ECONOMICS, 1995, 14 (02) :171-189

[36] Nosocomial infections in a pediatric ward: epidemiology and quality research [J].

Le Roux, P ;

Marshall, B ;

Toutain, F ;

Mary, JF ;

Pinon, G ;

Briquet, E ;

Le Luyer, B .

ARCHIVES DE PEDIATRIE, 2004, 11 (08) :908-915

[37] Hospitalizations associated with rotavirus gastroenteritis in Spain, 2001-2005 [J].

Lopez-de-Andres, Ana ;

Jimenez-Garcia, Rodrigo ;

Carrasco-Garrido, Pilar ;

Alvaro-Meca, Alejandro ;

Galarza, Patricia Graciela ;

de Miguel, Angel Gil .

BMC PUBLIC HEALTH, 2008, 8 (1)

[38] Exploring the cost effectiveness of an immunization programme for rotavirus gastroenteritis in the United Kingdom [J].

Lorgelly, P. K. ;

Joshi, D. ;

Gomara, M. Iturriza ;

Gray, J. ;

Mugford, M. .

EPIDEMIOLOGY AND INFECTION, 2008, 136 (01) :44-55

[39]

Mangen M. J. J., 2005, Acta Agricultura Scandinavica. Section C, Food Economics, V2, P35, DOI 10.1080/16507540510033451

[40] Cost-utility analysis to control Campylobacter on chicken meat-dealing with data limitations [J].

Mangen, Marie-Josée J. ;

Havelaar, Arie H. ;

Poppe, Krijn P. ;

Wit, G. Ardine de .

RISK ANALYSIS, 2007, 27 (04) :815-830

← 1 2 3 4 5 6 7 →